Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand – – $45.8 million Niktimvo™ (axatilimab-csfr) net ...

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Powerful tool can map gene regulation at single-nucleotide resolution

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
New Scientist

Does the family tree of ancient humans need a drastic rewrite?

Anthropologist Christopher Bae has recently suggested we add two new species of ancient human to our family tree. The plans break the conventions for how species should be named – but Bae argues the r ...

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN Session Date and Time: December 6, 2025; 9:30 AM – 11:00 AM ...
Nature

‘Biotech Barbie’ says the time has come to consider CRISPR babies. Do scientists agree?

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B ...